Pfizer Inc Cash Flow-to-Debt Ratio
Pfizer Inc cash flow-to-debt ratio. Pfizer Inc (PFIZ34) has a Cash Flow-to-Debt Ratio of 0.01x as of June 2026, meaning its operating cash flow of R$835.00 Million could theoretically repay 0% of its total liabilities (R$115.64 Billion) in one year. Check PFIZ34 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Pfizer Inc (2014–2025)
Cash flow-to-debt ratio of Pfizer Inc from 2014 to 2025. Historical debt coverage capacity for Pfizer Inc across 12 annual periods. Check how aggressively does Pfizer Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Pfizer Inc Cash Flow-to-Debt Ratio by Year (2014–2025)
Pfizer Inc cash flow-to-debt ratio by year from 2014 to 2025. Year-by-year debt coverage analysis for Pfizer Inc. For the full cash flow conversion analysis, see Pfizer Inc operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (BRL) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.10x | R$11.71 Billion | R$121.39 Billion | ▼ -5.5% |
| 2024 | 0.10x | R$12.74 Billion | R$124.90 Billion | ▲ +16.3% |
| 2023 | 0.09x | R$12.04 Billion | R$137.21 Billion | ▼ -69.6% |
| 2022 | 0.29x | R$29.27 Billion | R$101.55 Billion | ▼ -7.8% |
| 2021 | 0.31x | R$32.58 Billion | R$104.28 Billion | ▲ +97.4% |
| 2020 | 0.16x | R$14.40 Billion | R$90.99 Billion | ▲ +31.4% |
| 2019 | 0.12x | R$12.59 Billion | R$104.45 Billion | ▼ -26.9% |
| 2018 | 0.16x | R$15.83 Billion | R$96.02 Billion | ▼ -1.4% |
| 2017 | 0.17x | R$16.80 Billion | R$100.49 Billion | ▲ +15.7% |
| 2016 | 0.14x | R$16.19 Billion | R$112.07 Billion | ▲ +0.7% |
| 2015 | 0.14x | R$14.69 Billion | R$102.38 Billion | ▼ -19.4% |
| 2014 | 0.18x | R$17.08 Billion | R$95.94 Billion | — |